# A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease

> **NCT05541627** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AskBio France, SAS, a subsidiary of AskBio Inc.** · enrollment: 5 (actual)

## Conditions studied

- Huntington Disease

## Interventions

- **GENETIC:** AB-1001 Gene Therapy

## Key facts

- **NCT ID:** NCT05541627
- **Lead sponsor:** AskBio France, SAS, a subsidiary of AskBio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-10-12
- **Primary completion:** 2024-04-04
- **Final completion:** 2028-04
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2026-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05541627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05541627, "A Study to Evaluate AB-1001 Striatal Administration in Adults With Early Manifest Huntington's Disease". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT05541627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*